Brokerages forecast that Flex Pharma, Inc. (NASDAQ:FLKS) will report ($0.68) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Flex Pharma’s earnings, with estimates ranging from ($0.80) to ($0.56). Flex Pharma posted earnings per share of ($0.65) in the same quarter last year, which would suggest a negative year over year growth rate of 4.6%. The business is expected to report its next earnings report on Wednesday, November 1st.

According to Zacks, analysts expect that Flex Pharma will report full-year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($3.23) to ($2.18). For the next year, analysts expect that the company will report earnings of ($2.35) per share, with EPS estimates ranging from ($3.68) to ($1.37). Zacks’ earnings per share averages are an average based on a survey of research firms that that provide coverage for Flex Pharma.

Flex Pharma (NASDAQ:FLKS) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.12. Flex Pharma had a negative return on equity of 64.15% and a negative net margin of 2,410.97%. The firm had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.46 million.

Several research firms have commented on FLKS. Jefferies Group LLC reduced their price objective on Flex Pharma from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, May 4th. Zacks Investment Research downgraded Flex Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Flex Pharma presently has an average rating of “Buy” and a consensus price target of $15.40.

Several institutional investors have recently modified their holdings of the company. Primecap Management Co. CA boosted its stake in shares of Flex Pharma by 36.0% in the first quarter. Primecap Management Co. CA now owns 1,472,800 shares of the biotechnology company’s stock worth $6,480,000 after buying an additional 390,200 shares during the period. Royce & Associates LP boosted its stake in shares of Flex Pharma by 255.1% in the first quarter. Royce & Associates LP now owns 242,200 shares of the biotechnology company’s stock worth $1,066,000 after buying an additional 174,000 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Flex Pharma during the first quarter worth approximately $223,000. C WorldWide Group Holding A S boosted its stake in shares of Flex Pharma by 11.2% in the first quarter. C WorldWide Group Holding A S now owns 278,060 shares of the biotechnology company’s stock worth $1,223,000 after buying an additional 28,060 shares during the period. Finally, LMR Partners LLP bought a new position in Flex Pharma during the second quarter valued at about $104,000. 29.17% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This report was originally published by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

Shares of Flex Pharma (NASDAQ FLKS) traded down 1.02% on Monday, hitting $3.88. The stock had a trading volume of 27,775 shares. The firm’s market cap is $66.46 million. The firm’s 50-day moving average price is $3.89 and its 200 day moving average price is $3.96. Flex Pharma has a 52-week low of $3.01 and a 52-week high of $12.68.

Flex Pharma Company Profile

Flex Pharma, Inc is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.

Get a free copy of the Zacks research report on Flex Pharma (FLKS)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Flex Pharma (NASDAQ:FLKS)

Receive News & Ratings for Flex Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flex Pharma Inc. and related companies with's FREE daily email newsletter.